tirzepatide microdosing study Microdosing: The Growing Off-Label Trend You Should Know About Microdosing Tirzepatide Clicks: How Many

It may be accompanied by dyspnea, diaphoresis, nausea, lightheadedness, or a sense of impending doom

Gut bacteria-derived 5-hydroxyindole is a potent stimulant of intestinal motility via its action on L-type calcium channels

Lewis Lujan LM, McCarty MF, Di Nicolantonio JJ, Galvez Ruiz JC, Rosas-Burgos EC, Plascencia-Jatomea M, Iloki Assanga SB

Farxiga/Forxiga is not currently approved for weight loss as a standalone indication in non-diabetics, but the evidence is accumulating: Currently, if weight loss is the primary goal in a non-diabetic patient, GLP-1 agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) produce substantially greater weight loss (1015% vs 24%)